Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics Poster I

Date: Monday, November 9, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1917

Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1920

Differential Production of Th17-Related Cytokines By Toll like Receptor (TLR)-Ligands-Stimulated Monocyte-Derived Dendritic Cells (Mo-DCs) from Systemic Sclerosis (SSc) Patients; Relevance of IL-22 and IL-33 According to Disease Subtype and Stage

9:00AM-11:00AM: Abstract Number: 1919

Genetic Deletion of Toll-like Receptor 4 (Tlr4) Abrogates TGF-β1-Induced Endothelial-to-Mesenchymal Transition (EndoMT) in Murine Pulmonary Endothelial Cells

9:00AM-11:00AM: Abstract Number: 1912

Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Immune Abnormalities in Animal Models of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1910

Increased Circulating CD204/CD206 Double Positive Monocyte/Macrophages in Systemic Sclerosis Patients with “Early” Capillaroscopic Pattern of Microvascular Damage

9:00AM-11:00AM: Abstract Number: 1924

Increased Stat1 and Stat 1 Phosphorylation in Patients with Systemic Sclerosis (SSc)

9:00AM-11:00AM: Abstract Number: 1907

Inhibition of Phosphodiesterase 4 (PDE4) Reduces Dermal Fibrosis By Interfering with the Release of Pro-Fibrotic Cytokines from M2-Macrophages

9:00AM-11:00AM: Abstract Number: 1925

Interleukin-35 Is Upregulated in Systemic Sclerosis and Its Serum Levels Are Increased in Early Disease

9:00AM-11:00AM: Abstract Number: 1928

Isolation and Initial Characterization of Dermal Vascular Smooth Muscle Cells in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1913

Lysyl Oxidase Induces Fibrosis Via Upregulation of IL-6 and Serves As a Biomarker to Monitor Response to Therapy

9:00AM-11:00AM: Abstract Number: 1908

Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma Associated with Altered Tgfbeta/BMPR2 Signalling

9:00AM-11:00AM: Abstract Number: 1911

Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma

9:00AM-11:00AM: Abstract Number: 1909

Nailfold Capillaroscopic Assessment and Vascular Biomarkers in Systemic Sclerosis: Low CD40L Levels in Patients with Late Scleroderma Patterns

9:00AM-11:00AM: Abstract Number: 1914

Oncostatin M As a Potential Molecular Target in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1915

Pathogenetic Overlap Between Localised and Systemic Scleroderma: A Study of Nodular and Keloidal Morphea Occurring in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1922

Peripheral B Lymphocytes Secrete Both Interleukin 6 and Transforming Growth Factor-Beta and Potentiate Fibroblast Activation in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1918

Pharmacologic Targeting of Mitochondrial Dysfunction in Systemic Sclerosis: Enhanced SIRT3 Signaling

9:00AM-11:00AM: Abstract Number: 1921

Role of TLRs in the Abnormal Secretion of CXCL-4 By Plasmacytoid Dendritic Cells of Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1927

Salinomycin Induces Potent Suppression of TGF-β1-Mediated Expression of Profibrotic Genes in Cultured Dermal Fibroblasts from Normal Donors and from Donors with Systemic Sclerosis (SSc): A Novel Anti-Fibrotic Treatment for Tissue Fibrosis in SSc

9:00AM-11:00AM: Abstract Number: 1906

Stimulators of Soluble Guanylate Cyclase (sGC) Improve Wound Healing in the Tsk-1 Mouse Skin Fibrosis Mode

9:00AM-11:00AM: Abstract Number: 1905

Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit Experimental Skin Fibrosis of Different Aetiologies

9:00AM-11:00AM: Abstract Number: 1923

The Role of Inflammatory Myeloid Cell Compartment in Myocardial Fibrogenesis and Remodelling in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1916

Validation of Novel Biomarker Candidates for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1926

Wnt5a Activates Wnt/PCP-Signaling to Promote Fibroblast Activation and Fibrosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].